DF
VRTX icon

Dunhill Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Dunhill Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Sell
24
-1
-4% -$443 ﹤0.01% 554
2026
Q1 		$11.4K Buy
25
+4
+19% +$1.86K ﹤0.01% 519
2025
Q4 		$9.54K Buy
21
+2
+11% +$862 ﹤0.01% 506
2025
Q3 		$7.34K Sell
19
-10
-34% -$4.18K ﹤0.01% 517
2025
Q2 		$13.2K Sell
29
-8
-22% -$3.69K ﹤0.01% 403
2025
Q1 		$18.2K Sell
37
-5
-12% -$2.33K 0.01% 308
2024
Q4 		$17K Sell
42
-16
-28% -$7.42K 0.01% 296
2024
Q3 		$27.1K Buy
58
+24
+71% +$11.5K 0.01% 230
2024
Q2 		$15.7K Buy
34
+5
+17% +$2.17K 0.01% 240
2024
Q1 		$12.1K Buy
29
+3
+12% +$1.27K 0.01% 213
2023
Q4 		$10.6K Buy
+26
New +$9.61K 0.01% 201

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dunhill Financial's VRTX Position: Q2 2026 in Review

Dunhill Financial reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $443 and leaving 24 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #554.

Dunhill Financial first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $27.1K in Q3 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Dunhill Financial held 24 shares of Vertex Pharmaceuticals worth $11.9K as of Q2 2026.
  • Dunhill Financial sold 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
  • Vertex Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #554 holding.
  • Dunhill Financial first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Dunhill Financial's Vertex Pharmaceuticals position peaked at $27.1K in Q3 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.